- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03122184
Positive Psychology for Acute Coronary Syndrome Patients (PEACE-IV)
May 6, 2020 updated by: Jeff C. Huffman, MD, Massachusetts General Hospital
Positive Psychology for Acute Coronary Syndrome Patients: a Randomized, Controlled Pilot Trial
This is a randomized controlled pilot trial in approximately 50 acute coronary syndrome patients to determine if a 12 week, telephone-delivered, combined positive psychology-motivational interviewing intervention is feasible and more effective than a motivational interviewing health education program at improving health behaviors and other outcomes.
The investigators hypothesize that the intervention will be associated with better mental and physical health outcomes and better health behavior adherence compared to the motivational interviewing health education program.
Study Overview
Status
Completed
Conditions
Detailed Description
The initial study visit will occur in-person two weeks after discharge from the hospital.
Participants will meet with a member of the study staff (the study "trainer") and complete self-report questionnaires assessing health behavior adherence and mental and physical health.
Then, participants will be randomized to receive the positive psychology + motivational interviewing or the motivational interviewing health education interventions.
A study interventionist will provide a treatment manual specific to their condition, review the rationale for the initial exercise, and assign the first exercise.
If the participant is in the positive psychology + motivational interviewing condition, the trainer will explain the rationale for both the positive psychology and goal-setting portions of the program, and will be assigned the first exercise.
Similarly, if the participant is randomized into the motivational interviewing health education program, the interventionist will introduce them to the program and assign the first exercise.
Participants in both groups will then be given an accelerometer, which they will be asked to wear for 7 days to ensure that they are comfortable with the device and that useable data can be obtained from the participant.
Participants in both groups will then complete twelve 30-minute weekly phone sessions with a study trainer.
The phone sessions primarily will include a review of the prior week's session content and a discussion of the rationale and assignment of the next week's exercise/assignment.
Upon the completion of these calls, and again at a final follow-up timepoint at 24 weeks, a blinded member of the study staff will call participants to administer self-report outcome measures.
Participants will also be asked to wear an accelerometer at each of these follow-up timepoints as an objective measure of physical activity, which they will return by mail to the study staff.
Study Type
Interventional
Enrollment (Actual)
69
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult patients admitted to Massachusetts General Hospital or Brigham and Women's Hospital inpatient units
- Diagnosis of acute coronary syndrome (using established criteria for myocardial infarction or unstable angina; confirmed via medical record and/or patient's treatment team)
- Age 18 or older
- Suboptimal adherence on MOS-SAS: Score < 15 OR Score = 15 with physical activity < 6
Exclusion Criteria:
- Cognitive deficits, assessed via a 6-item cognitive screen used to assess appropriate participation of medically ill patients in research studies.
- Medical conditions precluding interviews or likely to lead to death within 6 months, determined in consultation with the primary treatment team and cardiology co-investigator.
- Inability to perform moderate to vigorous physical activity, as defined by an inability to walk without aid of an assistive device such as a walker or cane, OR inability to walk at a steady pace for at least 5 minutes without stopping.
- Inability to communicate in English.
- Inability to participate in physical activity
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Positive Psychology + Motivational Interviewing
Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity.
Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
|
For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise.
For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week.
Study trainers will use motivational interviewing techniques to facilitate goal setting.
|
Active Comparator: Motivational Interviewing Health Education
Participants will speak on the telephone each week with a study trainer.
During these calls, the trainer will provide education about a health behavior (physical activity, medication adherence, diet, stress reduction) and assign an activity related to one health behavior each week.
Motivational interviewing techniques will be used throughout to facilitate health behavior changes.
|
Each week, participants will learn about a different health behavior topic related to cardiac health.
They will also be introduced to motivational interviewing topics in concert with the health behavior education topics.
The intervention is divided into five sections, focusing on five different important cardiac health-related topics (recovery from an acute cardiac illness, physical activity, a heart-healthy diet, medication adherence, and stress reduction).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of the PP-MI Based Health Behavior Intervention
Time Frame: 24 weeks
|
Feasibility will be measured by examining the number of completed exercises.
|
24 weeks
|
Acceptability of the PP-MI Exercises: Utility Score
Time Frame: Weeks 1-12
|
Participants will provide ratings of utility after each exercise, measured on a 10-point Likert scale (0=not at all helpful; 10=very helpful).
Weekly utility ratings were averaged to provide an overall utility score of the exercises.
|
Weeks 1-12
|
Acceptability of the PP-MI Exercises: Ease Score
Time Frame: Weeks 1-12
|
Participants will provide ratings of ease after each exercise, measured on a 10-point Likert scale (0=very difficult; 10=very easy).
Weekly ratings were averaged to provide an overall ease of the exercises.
|
Weeks 1-12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Minutes of Moderate to Vigorous Physical Activity (Actigraph)
Time Frame: MVPA at 12 weeks and 24 weeks
|
ActiGraph GT3X+ step counters are validated as measures of physical activity and have been used in numerous studies of physical activity in patients with medical illness.
In this trial, participants will wear the accelerometer for one week at 12 weeks, and another week at 24 weeks to assess the feasibility of doing so and to ensure adequate capture of physical activity.
In our analysis, data on pre-ACS activity was collected using the International Physical Activity Questionnaire (IPAQ) to control for baseline activity.
|
MVPA at 12 weeks and 24 weeks
|
Change in Medication Adherence
Time Frame: Change in score from Baseline to 12 weeks, 24 weeks
|
Measured by Self-Reported Medication Adherence (SRMA), a two-item self-report medication adherence scale measuring percentage of time (in 10% increments) patients report taking their heart medications in the past one and two weeks.
Minimum: 0, Maximum:100.
Change was calculated by subtracting the score at baseline from the score at 12 weeks and 24 weeks.
Higher score indicates greater levels of medication adherence.
|
Change in score from Baseline to 12 weeks, 24 weeks
|
Change in Dietary Adherence
Time Frame: Change in score from Baseline to 12 weeks, 24 weeks
|
Measured by the MEDFICTS scale, a National Cholesterol Education Program-developed scale inquiring about saturated fat.
Minimum= 0; Maximum= 216.
Change was calculated by subtracting the score at baseline from the score at 12 and 24 weeks.
Higher scores indicate lower levels of dietary adherence.
|
Change in score from Baseline to 12 weeks, 24 weeks
|
Change in Positive Affect
Time Frame: Change in score from Baseline to 12 weeks, 24 weeks
|
The positive affect items on the Positive and Negative Affect Schedule (PANAS), a well-validated scale used in other intervention trials and in patients with medical illnesses, will be used to measure positive affect.
(Range: 10-50).
Change was calculated by subtracting the score at baseline from the score at 12 and 24 weeks.
Higher scores indicate higher levels of positive affect.
|
Change in score from Baseline to 12 weeks, 24 weeks
|
Change in Trait Optimism
Time Frame: Change in score from baseline to 12 week, 24 week
|
Life Orientation Test-Revised is a well-validated 6-item instrument used to measure dispositional optimism.
(Range: 0-24) Change was calculated by subtracting the score at baseline from the score at 12 and 24 weeks.
Higher scores indicate higher levels of optimism.
|
Change in score from baseline to 12 week, 24 week
|
Change in State Optimism
Time Frame: Change of score from Baseline to 12 weeks, 24 weeks
|
Measured by the State Optimism Scale developed by our team (SOM), which aims to capture the changeable nature of optimism based on time and situation.
Minimum:7, Maximum:35.
The higher number indicates a greater level of optimism.
Change was calculated by subtracting the score at baseline from the score at 12 and 24 weeks.
|
Change of score from Baseline to 12 weeks, 24 weeks
|
Changes in HADS-A Scores
Time Frame: Change in score from Baseline to 12 week, 24 week
|
The Hospital Anxiety and Depression Scale will be used to measure depression and anxiety.
This is a well-validated scale with few somatic symptom items that can confound mood/anxiety assessment in medically-ill patients.
(Range: 0-21) Change was calculated by subtracting the score at baseline from the score at 12 and 24 weeks.
Higher scores indicate higher levels of anxiety.
|
Change in score from Baseline to 12 week, 24 week
|
Change in HADS-D Scores
Time Frame: Change in score from Baseline to 12 week, 24 week
|
The Hospital Anxiety and Depression Scale will be used to measure depression and anxiety.
This is a well-validated scale with few somatic symptom items that can confound mood/anxiety assessment in medically-ill patients.(Range:
0-21).
Change was calculated by subtracting the score at baseline from the score at 12 and 24 weeks.
Higher scores indicate worse outcome (i.e.
greater levels of depression).
|
Change in score from Baseline to 12 week, 24 week
|
Change in Physical Function
Time Frame: Change of score from Baseline to 12 week, 24 week
|
Measured by the Duke Activity Status Index (DASI), a 12-item questionnaire that inquires about activities of daily living, basic physical activity, and more strenuous physical function to gauge overall functional capacity.
Minimum: 0, Maximum: 58.2.
Change was calculated by subtracting the score at baseline from the score at 12 and 24 weeks.
Higher scores indicate greater levels of functional capacity.
|
Change of score from Baseline to 12 week, 24 week
|
Change in SF-12 Scores (Physical)
Time Frame: Change of score from Baseline to 12 week, 24 week
|
The Medical Outcomes Study Short Form-12 (SF-12) will be used to measure quality of life.
This is an instrument which has been used in multiple cardiac studies in the past.
(SF-12 Mental Composite Score and Physical Composite Score Range: 0-100 each).
Change was calculated by subtracting the score at baseline from the score at 12 and 24 weeks.
Higher scores indicate higher level of health related QoL.
|
Change of score from Baseline to 12 week, 24 week
|
Change in SF-12 Scores (Mental)
Time Frame: Change of score from baseline to 12 and 24 weeks.
|
The Medical Outcomes Study Short Form-12 (SF-12) will be used to measure quality of life.
This is an instrument which has been used in multiple cardiac studies in the past.
(SF-12 Mental Composite Score and Physical Composite Score Range: 0-100 each).
Change was calculated by subtracting the score at baseline from the score at 12 and 24 weeks.
Higher scores indicate higher level of health related QoL.
|
Change of score from baseline to 12 and 24 weeks.
|
Change in Adherence to Health Behaviors
Time Frame: Change of score from Baseline to 12 week, 24 week
|
Three Medical Outcomes Study Specific Adherence Scale (MOS SAS) items assessing medication, diet, and exercise, will be measured individually and as a composite score.
(Range: 3-18) Change was calculated by subtracting the score at baseline from the score at 12 and 24 weeks.
Higher scores indicate better adherence to health behaviors.
|
Change of score from Baseline to 12 week, 24 week
|
Change in Cardiac Symptoms
Time Frame: Change of score from Baseline to 12 week, 24 week
|
Measured by a checklist taken from the Women and Ischemia Syndrome Evaluation Study (WISE) to assess the presence and intensity of ten cardiac symptoms felt to best capture the range of symptoms experienced by ACS patients.
Minimum: 0, Maximum: 30.
Change was calculated by subtracting the score at baseline from the score at 12 and 24 weeks.
Higher scores indicate greater levels of cardiac symptoms.
|
Change of score from Baseline to 12 week, 24 week
|
Change in Physical Activity
Time Frame: Change of score from Baseline to 12 week, 24 week
|
Measured by the self-report International Physical Activity Questionnaire (IPAQ).
The measure asseses the types of intensity of physical activity that people do as part of their daily lives.
All activities are converted to multiples of resting energy expenditure (MET) minutes per week.
Change was calculated by subtracting the score at baseline from the score at 12 and 24 weeks.
|
Change of score from Baseline to 12 week, 24 week
|
Change in Perceived Stress
Time Frame: Change of score from Baseline to 12 week, 24 week
|
Measured by the Perceived Stress Scale (PSS-4) measure.
Minimum: 0, Maximum: 16.
Change was calculated by subtracting the score at baseline from the score at 12 and 24 weeks Higher scores indicate greater levels of stress.
|
Change of score from Baseline to 12 week, 24 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jeff Huffman, MD, Massachusetts General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2017
Primary Completion (Actual)
July 10, 2018
Study Completion (Actual)
November 26, 2018
Study Registration Dates
First Submitted
April 6, 2017
First Submitted That Met QC Criteria
April 17, 2017
First Posted (Actual)
April 20, 2017
Study Record Updates
Last Update Posted (Actual)
May 14, 2020
Last Update Submitted That Met QC Criteria
May 6, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01HL113272 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ACS - Acute Coronary Syndrome
-
Canadian Institutes of Health Research (CIHR)Completed
-
Fundación Investigación Sanitaria en LeónAstraZenecaCompleted
-
Uppsala UniversityAbbott Medical Devices; The Medicines Company; InfraredxCompletedAcute Coronary Syndrome (ACS)Sweden
-
The Medicines CompanyCompletedAcute Coronary Syndrome (ACS)United States
-
Hainan People's HospitalRecruiting
-
AstraZenecaCompletedAcute Coronary Syndrome (ACS)China
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Yonsei UniversityCompletedAcute Coronary Syndrome (ACS)Korea, Republic of
-
Yun Dai ChenUnknownACS - Acute Coronary SyndromeChina
Clinical Trials on Positive Psychology + Motivational Interviewing
-
Massachusetts General HospitalRecruitingDiabetes Mellitus, Type 2United States
-
Massachusetts General HospitalRecruitingAcute Coronary Syndrome | Physical InactivityUnited States
-
Northwestern UniversityTerminatedACS - Acute Coronary SyndromeUnited States
-
Massachusetts General HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...Completed
-
Massachusetts General HospitalCompletedType 2 Diabetes MellitusUnited States
-
Massachusetts General HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedAcute Coronary SyndromeUnited States
-
Massachusetts General HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...Recruiting
-
Massachusetts General HospitalCompletedType2 DiabetesUnited States
-
Swiss Paraplegic Research, NottwilCompletedChronic Pain | Spinal Cord InjurySwitzerland
-
The Hong Kong Polytechnic UniversityRecruitingAdolescent DevelopmentHong Kong